Genomics In Cancer Care Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Genomics In Cancer Care Market Trends and Insights

Growing Burden of Cancer & Earlier Screening Programs

Robust growth in global cancer incidence is compelling health-system planners to shift resources toward preventive genomic screening. Latin America alone projects a 66% rise in cancer cases by 2040, intensifying pressure to catch malignancies at sub-clinical stages. U.S. agencies embraced blood-based detection when the FDA cleared Guardant Health’s Shield test for colorectal screening in adults aged 45 and older, setting a precedent for non-invasive assays.^{[1]U.S. Food and Drug Administration, “FDA Takes Action to Ensure Safety and Effectiveness of Laboratory Developed Tests,” fda.gov} Large population trials such as the National Cancer Institute’s Vanguard study employ the same platform to test multi-cancer detection across diverse cohorts. These developments create long-term reimbursement pathways, foster payer confidence, and bolster recurring revenue streams for test developers while lowering downstream treatment costs.

Increasing Adoption Of NGS-Based Comprehensive Genomic Profiling

Oncology practices are migrating from sequential single-gene tests toward expansive panels that interrogate hundreds of loci in one run. Evidence from the GOZILA trial showed patients guided by the Guardant360 CDx liquid biopsy achieved a median overall survival of 18.6 months compared with 9.9 months under standard care. Illumina’s TruSight Oncology Comprehensive became the first FDA-cleared kit with pan-cancer companion-diagnostic claims.^{[2]Illumina, Inc. "FDA Approves Next-Generation Cancer Biomarker Test and Companion Diagnostics." MyADLM, November 1, 2024.} Coupled with AI analytics, laboratories now deliver clinically actionable reports within days, and U.S. Medicare increasingly reimburses broad panels over iterative assays, accelerating mainstream uptake.

Rapid Cost Decline of Sequencing & Digital PCR Reagents

PacBio’s SPRQ chemistry for Revio systems cut HiFi whole-genome sequencing costs below USD 500 while preserving accuracy. The University of Minnesota Genomics Center reported an additional 20% drop after adopting AVITI technology, surpassing Illumina NovaSeq X Plus on cost-per-gigabase metrics. Roche’s sequencing-by-expansion prototypes promise throughput capable of seven 30× human genomes per hour. These breakthroughs help institutions in emerging economies overcome budget barriers and lay the groundwork for point-of-care genomic testing models.

Scaling Liquid-Biopsy Pipelines for Minimal-Residual-Disease (MRD) Monitoring

Exact Sciences’ OncoDetect test identifies colorectal-cancer recurrence up to two years earlier than imaging by scanning 200 ctDNA variants. A 2,000-patient colon-cancer study showed 62.6% of ctDNA-positive cases relapsed within three years versus 15.4% of ctDNA-negative cases, reinforcing MRD’s prognostic power. The FDA guidance on ctDNA endpoints sponsors use liquid biopsy for accelerated approval pathways.^{[3]Food and Drug Administration. "Medical Devices; Laboratory Developed Tests." Federal Register, May 6, 2024.} With CMS covering Guardant Reveal in postoperative surveillance, economic and regulatory alignment is propelling wide adoption.

Shortage Of Accredited Molecular Pathologists

Worldwide demand for professionals who can translate multi-omic data into clinical action far exceeds supply. Training requirements encompass molecular biology, bioinformatics, and oncology subspecialties, competencies that extend beyond legacy pathology curricula. Emerging economies face added challenges as talent migrates to higher-income regions. AI tools lighten routine interpretation workloads, yet regulations still require board-certified oversight for final sign-off. Fast-track certification programs are under development, but workforce expansion will lag market growth for several years.

Persistently High Total-Cost-Of-Ownership for WGS Platforms

While reagent costs keep falling, capital outlays for high-throughput sequencers, environmental controls, secure data storage, and specialized staffing remain steep. Mid-sized hospitals in emerging economies must often send samples to external reference labs, slowing turnaround and limiting the accrual of in-house expertise. Cloud bioinformatics services reduce hardware needs, but data-sovereignty rules and cybersecurity obligations raise separate compliance expenses. Sequencing-as-a-service models continue to mature, yet have not fully resolved budget constraints.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Services Drive Growth Despite Instruments Dominance

Instruments represented the largest revenue pool, holding 37.80% share of the genomics in the cancer care market in 2025. Demand reflected ongoing platform refresh cycles as users swapped legacy sequencers for higher-throughput, longer-read systems. Consumables sales expanded in line with test-volume growth, while point-of-care cartridges opened new, decentralized channels.

Services are accelerating at an 18.35% CAGR, underscoring a shift toward data interpretation, cloud analytics, and integrated clinical reporting. Guardant Health’s 31% revenue jump to USD 737 million during 2024 shows the pull of recurring testing and bioinformatics fees. Hospitals increasingly outsource bioinformatics to mitigate staffing shortages, and bundled, end-to-end service contracts now cover sample logistics, sequencing, interpretation, and decision-support updates. This evolution positions service providers as strategic partners rather than transactional suppliers within the genomics in cancer care market.

By Technology: Single-Molecule Sequencing Disrupts NGS Dominance

Genome sequencing platforms based on short-read NGS secured 45.70% market share in 2025, supported by established laboratory workflows and extensive clinical evidence. Yet single-molecule, real-time sequencing is expanding at a startling 22.85% CAGR as oncologists seek structural-variant resolution in repeat-rich regions and methylation layers unavailable from short reads.

Oxford Nanopore’s latest chemistry generated complete chromosome assemblies and simultaneous epigenetic maps, demonstrating the clinical readiness of long-read approaches. Meanwhile, Roche’s sequencing-by-expansion prototypes promise to merge long reads with high throughput, threatening to redraw product-replacement cycles. PCR-based kits retain value for low-plex companion diagnostics and rapid EGFR or KRAS checks, yet microarrays are ceding ground as sequencing prices near parity. Technology diversity ensures that laboratories can align platform choice with specific oncology use cases inside the genomics in cancer care market.

By Application: MRD Monitoring Accelerates Beyond Diagnostics

Diagnostics maintained 52.00% of the genomics in the cancer care market size in 2025 through entrenched companion-diagnostic pathways and payer familiarization. Routine EGFR, BRAF, and PIK3CA panels anchor laboratory revenue streams. 

Minimal-residual-disease and liquid-biopsy assays, growing at a 20.65% CAGR, are redefining follow-up protocols. The SERENA-6 trials verified that ctDNA-guided treatment switches halve the progression risk for ER-positive breast-cancer patients with emergent ESR1 mutations. Pharma sponsors now embed MRD endpoints in adjuvant-therapy trials, which reinforce assay volumes post-approval. Drug-discovery genomics and precision-oncology decision platforms further enlarge the pipeline, supplying biomarker insights during early clinical development and supporting adaptive trial designs.

By End-user: Reference Labs Gain Share Through Specialized Capabilities

Hospitals and cancer centers generated 41.10% of 2025 revenue, leveraging on-site pathology and integrated care teams to run high-throughput panels for newly diagnosed patients. Yet reference and clinical laboratories exhibit the fastest momentum at 17.35% CAGR, bolstered by economies of scale and capital-intensive automation that lower per-sample costs.

Labcorp’s partnership with Ultima Genomics to expand whole-genome offerings and to launch Plasma Detect ctDNA MRD illustrates reference labs’ strategic positioning. Pharmaceutical and biotech firms intensify demand for high-complexity assays to stratify trial subjects, while academic institutes pilot novel technologies before broader rollout. Together, these segments create a complementary ecosystem in which centralized expertise coexists with bedside sequencing in the genomics market for cancer care.

Geography Analysis

North America led with 36.60% market share in 2025, supported by broad payer coverage, a mature clinical-trial network, and stringent but predictable regulatory oversight. The FDA’s May 2024 Laboratory Developed Tests final rule aligned quality requirements across commercial and academic laboratories. Parallel Medicare decisions extended reimbursement to liquid-biopsy-based MRD surveillance, unlocking sizable, recurring test volumes. Cross-industry collaborations ensure rapid migration of research innovations into front-line clinical practice, consolidating the region’s leadership in the genomics in cancer care market.

Asia Pacific records the fastest regional CAGR at 14.55% to 2031. National genome programs in China, Japan, Singapore, and the United Arab Emirates underpin large-scale sequencing infrastructure and create fertile ground for early screening pilots. Ongoing investment in Saudi Arabia’s precision-medicine corridor, combined with streamlined regulatory pathways in the United Arab Emirates, attracts multinational diagnostics firms to establish regional hubs. Rising cancer incidence and widening insurance coverage accelerate demand, while local manufacturing partnerships drive down consumables’ costs, improving accessibility.

Europe remains a critical pillar of global adoption through coordinated regulatory and value-assessment frameworks. The European Commission’s conditional approval of Illumina’s divestment plan for GRAIL removed a legal logjam, restoring competitive balance and allowing pan-European multi-cancer screening pilots to proceed. Meanwhile, the EU In Vitro Diagnostic Regulation enforces stringent clinical-evidence requirements, boosting confidence among physicians and payers. Standard-setting bodies such as the European Liquid Biopsy Society publish harmonized protocols that foster reproducibility across laboratories. In combination, these measures sustain healthy growth despite mature infrastructure.

Regulatory Landscape

Regulation for genomics in cancer care continues to tighten around test validity, software and bioinformatics controls, and clinical evidence. In the United States, FDA device classifications and special controls have been applied to sequencing constituents (including whole-exome-sequencing-related devices, effective September 2024), while 21 CFR 866.6080 sets expectations for labeling and limitations around the clinical significance of findings for NGS-based tumor profiling tests. Reimbursement policy also shapes adoption, with CMS maintaining national coverage for NGS testing for Medicare beneficiaries with advanced cancer when performed in CLIA-certified laboratories.

Outside the United States, national health systems are formalizing pathways that move genomics from pilots into routine care. Cancer Australia released its National Framework for Genomics in Cancer Control in January 2025 to guide equitable access and implementation, and NHS England announced a national genetic register in January 2026 to support systematic follow-up and targeted screening for inherited cancer risk. In Europe, the EMA updated its Qualification of Novel Methodologies guidance (Revision 6, June 2026), reinforcing structured evidence generation for emerging methodologies used in medicinal product development and companion diagnostic-enabled precision oncology.

Value Chain Analysis

The value chain covers assay and platform design (sequencing chemistry, library prep, and panel design), instrument and reagent manufacturing (sequencers, PCR systems, consumables), and sample acquisition and preparation (tissue and liquid biopsy workflows, including FFPE processing). It then moves through analytical validation and clinical deployment in CLIA/ISO-aligned laboratories, bioinformatics and reporting (pipelines, variant interpretation, AI-driven decision support), and downstream clinical action (tumor boards, therapy selection, MRD monitoring, and longitudinal data management). Distribution is increasingly hybrid, combining direct sales of instruments and kits with sequencing-as-a-service, cloud analytics subscriptions, and enterprise contracts with hospitals, cancer centers, and reference laboratories.

Recent partnerships show where value accrues and where bottlenecks persist. Illumina expanded its collaboration with Labcorp in March 2026 to co-commercialize distributed IVD kits (including PGDx elio plasma focus Dx and TruSight Oncology Comprehensive), while Illumina also partnered with PREMIA to widen CGP access within Taiwan provider networks that already integrated CGP into national coverage in 2024. On the analytics side, SOPHiA GENETICS collaborations with MD Anderson (January 2026) and an MOU with Memorial Sloan Kettering Cancer Center (June 2026) highlight the growing role of platform-based data interpretation hubs. Workflow-enablement initiatives such as PacBio and Covaris (April 2026) target the large installed base of FFPE tumor samples, while CellCarta and Pillar Biosciences (April 2026) use kitted NGS panels to reduce trial screening friction across distributed laboratory networks.

Market Opportunities and Future Outlook

A major opportunity is the shift from episodic, single-timepoint profiling to longitudinal blood-based monitoring integrated into routine oncology workflows. Quest Diagnostics expanded access to its Haystack MRD ctDNA test and comprehensive genomic profiling by integrating ordering into Flatiron Healths OncoEMR for community oncology clinicians (July 2026), which lowers operational friction for repeat testing and supports broader use of MRD beyond large academic centers. Platform vendors and labs also have whitespace to package end-to-end services that address the shortage of accredited molecular pathologists by combining wet-lab execution with automated interpretation and report generation tools.

Multi-cancer early detection and ultra-sensitive MRD are also creating room for whole-genome and transcriptome-informed offerings paired with AI interpretation. Caris Life Sciences launched Caris Detect, a multi-cancer early detection blood test using ultra-deep WGS, WTS, and AI (July 2026), while GRAIL presented PATHFINDER 2 data at ASCO 2026 across 35,878 participants showing Galleri increased cancer detection 6.5-fold when added to standard screening. In MRD, Ultima Genomics presented TRACERx data at AACR 2026 describing ppmSeq performance with a 95% limit of detection below 3 parts per million, reinforcing demand for high-sensitivity approaches that broaden liquid biopsy into earlier disease settings and tighter recurrence surveillance. Together, these signals point to continued investment in distributed IVD kit strategies, automation, and data platforms that can scale interpretation and compliance across geographies.